|Mr. Ashleigh W. Palmer B.Sc., M.B.A.||Co-Founder, Pres, CEO & Director||900.3k||N/A||1963|
|Mr. Thierry Chauche||Chief Financial Officer||411.37k||N/A||1976|
|Dr. Eleanor L. Ramos M.D.||Chief Medical Officer||611.72k||N/A||1956|
|Dr. Francisco Leon M.D., Ph.D.||Co-Founder & Chief Scientific Officer||N/A||N/A||1972|
|Ms. Christina Yi||Chief Operations Officer||N/A||N/A||1976|
|Mr. Robert A. Doody Jr.||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Heidy Abreu King-Jones J.D., L.L.M.||Chief Legal Officer||N/A||N/A||1983|
|Kaelan Hollon||VP of Corp. Communications||N/A||N/A||N/A|
|Mr. Jason Levine||VP Marketing||N/A||N/A||N/A|
|Sarah O'Brien||Chief People Officer||N/A||N/A||N/A|
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 8.